Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compositions and synergistic methods for treating infections

A composition and treatment effect technology, applied in the field of compositions for enhancing host immune defense, can solve the problems of lack of treatment options for treating pathogen infection, poor infection type, etc.

Pending Publication Date: 2022-06-07
BIOAEGIS THERAPEUTICS INC +1
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Overuse and misuse of antimicrobials may be a factor in the growing problem of antimicrobial resistance, which will continue to lead to an increase in the types of pathogenic infections that respond poorly to previously effective antimicrobials
Antimicrobial resistance leads to lack of therapeutic options for treating pathogenic infections

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions and synergistic methods for treating infections
  • Compositions and synergistic methods for treating infections
  • Compositions and synergistic methods for treating infections

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0109] Preparation and Administration of Medication

[0110] The methods and compositions of the present invention have important implications for patient treatment and also for the clinical development of new treatments. It is also expected that clinical investigators will now use this method to determine entry criteria for human subjects in clinical trials. Healthcare practitioners choose treatment options based on the expected net benefit to the subject. The net benefit is derived from the risk-reward ratio.

[0111] The amount of treatment can be varied, eg, by increasing or decreasing the amount of gelsolin and / or antimicrobial agent administered to the subject, by varying the therapeutic composition administered, by varying the route of administration, by varying the timing of administration, and the like. The effective amount will vary depending on the particular infection or condition being treated, the age and physical condition of the subject being treated, the sev...

Embodiment 1

[0147] Antibiotic-resistant pneumococcal pneumonia occurs and can be a problem. Research has been conducted to evaluate new therapeutic strategies for fighting infections, including ways to enhance innate immunity. Experiments were performed to determine the effect of pGSN administration on macrophage and host survival.

[0148] method

[0149] Bacterial strains and cultures

[0150] Streptococcus pneumoniae serotype 3 (Cat. No. 6303, American Type Culture Collection, Rockville, MD) was grown overnight on agar plates supplemented with 5% sheep blood (Cat. No. 90001-282, VWR, West Chester, PA) and were prepared and quantified as previously reported (Yang Z. et al., Am J Physiol Lung Cell Mol Physiol 2015; 309:L11-6).

[0151] In vitro and in vivo procedures

[0152] (1) In vitro studies

[0153] In vitro studies were performed in which 125 to 250 μg / ml pGSN was added to bacterial cultures and bacterial survival was determined.

[0154] (2) In vivo studies

[0155] B16 mi...

Embodiment 2

[0161] Studies were conducted to evaluate the effect of pGSN treatment on antibiotic-sensitive and antibiotic-resistant mouse models of pneumococcal pneumonia.

[0162] method

[0163] Bacterial strains and cultures

[0164] S. pneumoniae serotypes 3 and 14 (catalog numbers 6303 and 700677, respectively) were obtained from the American Type Culture Collection (Rockville, MD). Serotype 3 bacteria were grown overnight on 5% sheep blood-supplemented agar dishes (Cat. No. 90001-282, VWR, West Chester, PA) and prepared and quantified as previously reported (YangZ. et al., Am J Physiol Lung Cell Mol Physiol 2015;309:L11-6). Because serotype 14 requires a more detailed protocol to achieve consistent results, the growth protocol reported in Restrepo AV et al., BMC Microbiol 2005;5:34 was performed using two consecutive Amplify and adjust bacterial concentration by OD600 for in vivo administration.

[0165] A mouse model of pneumococcal pneumonia

[0166] Normal 6 to 8 week (wk) o...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to compositions and methods for treating a microbial infection in a subject, in particular methods of administering a gelsolin agent and an antimicrobial agent to produce a synergistic therapeutic effect against a microbial infection in a subject. The invention also relates to methods for treating a viral infection in a subject, comprising methods comprising delayed ed-administration methods and / or synergistic methods.

Description

[0001] Related applications [0002] This application claims the benefit of US Provisional Application Serial No. 62 / 864,599, filed June 21, 2019, under 35 U.S.C. §119(e), the disclosure of which is incorporated herein by reference in its entirety. [0003] government interest [0004] This invention was made with government support under grants NIH AI125152 and NIH / NIAID contracts HHSN272201000033I-HHSN27200003 and HHSN272201000033I-HHSN27200006. The United States Government has certain rights in this invention. technical field [0005] In some aspects, the present invention relates to compositions and methods for enhancing host immune defenses in the treatment of microbial infections. Background technique [0006] Antimicrobial resistance is a global public health problem. Antimicrobial resistance is known to reduce the therapeutic efficacy of various antimicrobial agents, such as antibiotics, antivirals, antifungals, and antiparasitics. Examples of emerging resistant ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/17A61K45/06A61P31/00
CPCA61P31/00A61K45/06A61K31/43A61K31/407A61K38/1709Y02A50/30A61K2300/00A61P31/12A61P31/04A61K45/00
Inventor 马克·J·迪努比乐苏珊·L·莱文森托马斯·P·施托塞尔莱斯特·科布齐克
Owner BIOAEGIS THERAPEUTICS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com